Eisai sales and marketing update

Eisai launched Inovelon rufinamide oral suspension in Spain for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age and older. Eisai markets the triazole derivative in the U.S. as Banzel and in the EU as Inovelon. Rufinamide is also approved for the indication in Switzerland and Canada. The company declined to disclose Inovelon's price. ...